VRTX241227C405000
- 1.70
- 0.000.00%
Vertex Pharmaceuticals Newsroom
BofA Securities Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $522
Bank of America Securities Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Barclays Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $418
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $441
BMO Capital Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $520
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $418 to $575
Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)
Bernstein Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals: Balancing Growth Prospects and Uncertainties With a Hold Rating
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575
Stifel Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $494
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Vertex Pharmaceuticals (VRTX)
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575
Citi Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
Vertex Pharmaceuticals Analyst Ratings
Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $460
Wells Fargo Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Cuts Target Price to $460
Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Cuts Target Price to $456
Vertex Pharmaceuticals: Hold Rating Amid Mixed Results for Suzetrigine in LSR and Optimistic Prospects in Acute Pain